Hypertriglyceridemia - Pipeline Review, H2 2016

  • ID: 4030274
  • Report
  • 113 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acasti Pharma Inc
  • Akcea Therapeutics Inc
  • Allergan Plc
  • AstraZeneca Plc
  • BASF SE
  • Cardax Inc
  • MORE
Hypertriglyceridemia - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia - Pipeline Review, H2 2016, provides an overview of the Hypertriglyceridemia (Metabolic Disorders) pipeline landscape.

Hypertriglyceridemia is a condition in which triglyceride levels are elevated. Causes include diabetes mellitus, obesity, family history and sedentary habits. Symptoms include gastrointestinal pain, difficulty breathing, memory loss, dementia, xanthelasmas and corneal arcus. Treatment includes diuretics, beta-blockers, estrogen therapy and corticosteroids.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hypertriglyceridemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertriglyceridemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertriglyceridemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hypertriglyceridemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertriglyceridemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertriglyceridemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertriglyceridemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertriglyceridemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acasti Pharma Inc
  • Akcea Therapeutics Inc
  • Allergan Plc
  • AstraZeneca Plc
  • BASF SE
  • Cardax Inc
  • MORE
Introduction

Hypertriglyceridemia Overview

Therapeutics Development

Pipeline Products for Hypertriglyceridemia - Overview

Pipeline Products for Hypertriglyceridemia - Comparative Analysis

Hypertriglyceridemia - Therapeutics under Development by Companies

Hypertriglyceridemia - Therapeutics under Investigation by Universities/Institutes

Hypertriglyceridemia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Hypertriglyceridemia - Products under Development by Companies

Hypertriglyceridemia - Products under Investigation by Universities/Institutes

Hypertriglyceridemia - Companies Involved in Therapeutics Development

Acasti Pharma Inc

Akcea Therapeutics Inc

Allergan Plc

Alnylam Pharmaceuticals Inc

Arisaph Pharmaceuticals Inc

AstraZeneca Plc

BASF SE

Cardax Inc

Catabasis Pharmaceuticals Inc

Celon Pharma SA

CymaBay Therapeutics Inc

Gemphire Therapeutics Inc

Jeil Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

LipimetiX Development Inc

Matinas BioPharma Holdings Inc

Sancilio & Company Inc

Zydus Cadila Healthcare Ltd

Hypertriglyceridemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AEM-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2814 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-AC3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-ANG - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARI-3037MO - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bezafibrate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BioE-1115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BSN-272 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAT-2000 Series - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAT-2003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-085 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gemcabene calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icosabutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-ANGPTL3LRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-APOCIIILRX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LTPO-3FA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAT-9001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MN-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKPL-66 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omega-3-carboxylic acids - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saroglitazar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seladelpar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Hypertriglyceridaemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

volanesorsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypertriglyceridemia - Dormant Projects

Hypertriglyceridemia - Discontinued Products

Hypertriglyceridemia - Product Development Milestones

Featured News & Press Releases

Dec 19, 2016: Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen

Sep 14, 2016: Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data

Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions

May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen

Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia

Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims

Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA

Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine

May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia

Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia

Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial

Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results

Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C

Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014

Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Hypertriglyceridemia, H2 2016

Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Hypertriglyceridemia - Pipeline by Acasti Pharma Inc, H2 2016

Hypertriglyceridemia - Pipeline by Akcea Therapeutics Inc, H2 2016

Hypertriglyceridemia - Pipeline by Allergan Plc, H2 2016

Hypertriglyceridemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016

Hypertriglyceridemia - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016

Hypertriglyceridemia - Pipeline by AstraZeneca Plc, H2 2016

Hypertriglyceridemia - Pipeline by BASF SE, H2 2016

Hypertriglyceridemia - Pipeline by Cardax Inc, H2 2016

Hypertriglyceridemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016

Hypertriglyceridemia - Pipeline by Celon Pharma SA, H2 2016

Hypertriglyceridemia - Pipeline by CymaBay Therapeutics Inc, H2 2016

Hypertriglyceridemia - Pipeline by Gemphire Therapeutics Inc, H2 2016

Hypertriglyceridemia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016

Hypertriglyceridemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016

Hypertriglyceridemia - Pipeline by LipimetiX Development Inc, H2 2016

Hypertriglyceridemia - Pipeline by Matinas BioPharma Holdings Inc, H2 2016

Hypertriglyceridemia - Pipeline by Sancilio & Company Inc, H2 2016

Hypertriglyceridemia - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Hypertriglyceridemia - Dormant Projects, H2 2016

Hypertriglyceridemia - Dormant Projects (Contd..1), H2 2016

Hypertriglyceridemia - Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for Hypertriglyceridemia, H2 2016

Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acasti Pharma Inc
  • Akcea Therapeutics Inc
  • Allergan Plc
  • Alnylam Pharmaceuticals Inc
  • Arisaph Pharmaceuticals Inc
  • AstraZeneca Plc
  • BASF SE
  • Cardax Inc
  • Catabasis Pharmaceuticals Inc
  • Celon Pharma SA
  • CymaBay Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Jeil Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • LipimetiX Development Inc
  • Matinas BioPharma Holdings Inc
  • Sancilio & Company Inc
  • Zydus Cadila Healthcare Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll